| Title |
|
|
|
The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy
| |
| Author |
|
|
|
| |
| Institution/Organisation |
|
|
|
A0081007 Investigators
| |
| Abstract |
|
|
|
| We evaluated the efficacy of pregabalin in patients with chronic lumbosacral radiculopathy. This randomized, controlled, withdrawal trial included five phases: screening (418 days); run-in (410 days) to screen out placebo responders; single-blind (28 days) to identify pregabalin responders; double-blind to randomize responders to pregabalin or placebo (35 days); and final study medication taper (7 days). The primary endpoint was time to loss of response (LOR) during the double-blind phase (⩾1-point increase in pain, discontinuation, or rescue-medication use). In the single-blind phase, 58% of patients had ⩾30% pain reduction. In the double-blind phase, pregabalin (n = 110) and placebo (n = 107) groups did not differ significantly in time to LOR. Adverse events caused the discontinuation of 9.9% and 5.6% of pregabalin-treated and placebo-treated patients, respectively. Most patients with chronic lumbosacral radiculopathy responded to pregabalin therapy; however, time to LOR did not significantly differ between pregabalin and placebo. Considering the results of all phases of the study, it is difficult to draw definitive conclusions from it, suggesting a need for further work to understand the clinical potential of pregabalin treatment for lumbosacral radiculopathy. | | |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
Pain / International Association for the Study of Pain. - Amsterdam | |
| Publication |
|
|
|
Amsterdam : 2010
| |
| ISSN |
|
|
|
0304-3959
| |
| Volume/pages |
|
|
|
150:3(2010), p. 420-427
| |
| ISI |
|
|
|
000281675000012
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (publisher's version - intranet only) |
|
|
| | |
|